Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.44 |
| ▸ | PDE4A | P27815 | 10/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL673206 | 0.91 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL2979183 | 0.91 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL2966972 | 0.83 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL3550817 | 0.83 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL3554026 | 0.82 | PDE4A (0.50) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL4769350 | 0.80 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL3550320 | 0.80 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL1829130 | 0.79 | PDE4A (0.47) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL3553860 | 0.79 | PDE4A (0.47) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15252404 | 0.78 | PDE4A (0.46) | PDE4BPDE4APDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090148388-A1 | Isoindoline Compounds and Methods of Making and Using the Same | CELGENE CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-7495112-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070244183-A1 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION | 2007-10-18 | — | — | US | disclosed |
| US-7244759-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1778635-A2 | ISOINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CELGENE CORPORATION (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084815-A1 | Isoindoline compounds and methods of making and using the same | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006025991-A2 | ISOINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CELGENE CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148388-A1 | Isoindoline Compounds and Methods of Making and Using the Same | MCL1, HPGDS, TPMT | PDE4B 1194/4885PDE4A 1112/4885PDE4C 1258/4885 |
| US-20070244183-A1 | Isoindoline compounds and methods of making and using the same | MCL1, HPGDS, TPMT | PDE4B 1194/4885PDE4A 1112/4885PDE4C 1258/4885 |
| US-20060084815-A1 | Isoindoline compounds and methods of making and using the same | MCL1, HPGDS, TPMT | PDE4B 1194/4885PDE4A 1112/4885PDE4C 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.